Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review

被引：45

作者：

Kristensen, A. ^{[1
,2
]}

Vagnildhaug, O. M. ^{[1
,2
]}

Gromberg, B. H. ^{[1
,2
]}

Kaasa, S. ^{[1
,2
]}

Laird, B. ^{[1
,3
]}

Solheim, T. S. ^{[1
,2
]}

机构：

[1] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, European Palliat Care Res Ctr PRC, N-7034 Trondheim, Norway

[2] Univ Trondheim Hosp, St Olavs Hosp, Canc Clin, Trondheim, Norway

[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 99卷

关键词：

Quality of Life; Pancreatic Cancer; Pain; Cachexia; Chemotherapy; Systematic review; PHASE-III TRIAL; GEMCITABINE PLUS CAPECITABINE; PATIENT-REPORTED OUTCOMES; SINGLE-AGENT GEMCITABINE; COMPARING GEMCITABINE; CLINICAL BENEFIT; DOUBLE-BLIND; RANDOMIZED-TRIALS; 1ST-LINE THERAPY; LINE THERAPY;

D O I：

10.1016/j.critrevonc.2016.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy is increasingly being used in advanced pancreatic cancer, but side-effects are common. The aim of this systematic review was to assess whether chemotherapy improves health-related quality of life (HRQoL), pain or cachexia. Thirty studies were reviewed. Four of 23 studies evaluating HRQoL, 7 of 24 studies evaluating pain and 0 of 8 studies evaluating cachexia found differences between treatment arms. Change in HRQoL from baseline was evaluated in 14 studies: five studies reported an improvement in at least one treatment arm; three a worsening and the remaining stable scores. Change in pain intensity from baseline was evaluated in eight studies, and improvement was observed in seven. Of the four studies reporting improved survival, three reported improved HRQoL or pain. In conclusion, chemotherapy can stabilize HRQoL and improve pain control. Effects on cachexia are hard to elucidate. Improved survival does not come at the expense of HRQoL or pain control. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：286 / 298

页数：13

共 54 条

[1] Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer [J].

Abou-Alfa, Ghassan K. ;

Letourneau, Richard ;

Harker, Graydon ;

Modiano, Manuel ;

Hurwitz, Herbert ;

Tchekmedyian, Nerses Simon ;

Feit, Kevie ;

Ackerman, Judie ;

De Jager, Robert L. ;

Eckhardt, S. Gail ;

O'Reilly, Eileen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4441-4447

[2]

[Anonymous], J CLIN ONCOL

[3] Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone:: A randomized multicenter phase III clinical trial -: SAKK 44/00-CECOG/PAN.1.3.001 [J].

Bernhard, Juerg ;

Dietrich, Daniel ;

Scheithauer, Werner ;

Gerber, Daniela ;

Bodoky, Gyo Rgy ;

Ruhstaller, Thomas ;

Glimelius, Bengt ;

Bajetta, Emilio ;

Schueller, Johannes ;

Saletti, Piercarlo ;

Bauer, Jean ;

Figer, Arie ;

Pestalozzi, Bernhard C. ;

Hne, Claus-Henning Ko ;

Mingrone, Walter ;

Stemmer, Salomon M. ;

Tamas, Karin ;

Kornek, Gabriela V. ;

Koeberle, Dieter ;

Herrmann, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3695-3701

[4] Clinical Benefit Response in Pancreatic Cancer Trials Revisited [J].

Bernhard, Juerg ;

Dietrich, Daniel ;

Glimelius, Bengt ;

Bodoky, Gyoergy ;

Scheithauer, Werner ;

Herrmann, Richard .

ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (1-2) :42-48

[5] Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma [J].

Bonnetain, Franck ;

Dahan, Laetitia ;

Maillard, Emilie ;

Ychou, Marc ;

Mitry, Emmanuel ;

Hammel, Pascal ;

Legoux, Jean-Louis ;

Rougier, Philippe ;

Bedenne, Laurent ;

Seitz, Jean-Francois .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) :2753-2762

[6] A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].

Bramhall, SR ;

Schulz, J ;

Nemunaitis, J ;

Brown, PD ;

Baillet, M ;

Buckels, JAC .

BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167

[7] Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial [J].

Bramhall, SR ;

Rosemurgy, A ;

Brown, PD ;

Bowry, C ;

Buckels, JAC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3447-3455

[8] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[9] Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension [J].

Calvert, Melanie ;

Blazeby, Jane ;

Altman, Douglas G. ;

Revicki, Dennis A. ;

Moher, David ;

Brundage, Michael D. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08) :814-822

[10] Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials [J].

Ciliberto, Domenico ;

Botta, Cirino ;

Correale, Pierpaolo ;

Rossi, Marco ;

Caraglia, Michele ;

Tassone, Pierfrancesco ;

Tagliaferri, Pierosandro .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (03) :593-603

← 1 2 3 4 5 6 →